Dr WANG Yuliang    
王馭良

0000-0001-6975-4503

Biography

Dr. Yuliang WANG obtained his Master degree (Surgery) and completed his clinical training as a urologist in Peking University. After that, Dr. Wang continued his PhD study and postdoctoral research in the School of Biomedical Sciences at The Chinese University of Hong Kong (CUHK). Currently, he is working as a Research Assistant Professor in the Department of Surgery at CUHK.

Dr Wang’s current research work focuses on the prostate carcinogenesis. He has published more than 20 research papers in a number of prestigious journals, including Cancer Research, Oncogene, Molecular Aspects of Medicine and Endocrine-Related Cancer. As Principal Investigator, Dr. Wang obtained two National Natural Science Foundation of China (NSFC) grants (Young scientist and General programs). He also acts as Co-Is of various research fundings from RGC, ITF, and HMRF.

Research Interests

• Lineage plasticity in prostate cancer;
• Orphan nuclear receptors-mediated signaling pathways in prostate cancer;
• Transcriptional regulation of castration-resistant and neuroendocrine prostate cancer

Additional Information

Google Scholar Webpage: https://scholar.google.com/citations?user=dFw8Lm8AAAAJ

Selected Publications

1. Wang, Y., Fan, J., Chen, T., Xu L., Liu P., Xiao, L., Wu, T., Zhou, Q., Zheng, Q., Liu, C., Chan, F. L., and Wu, D (2022). A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer, Front Endocrinol (Lausanne), 13, 975623.
2. Wang, Y., Gao, W., Li, Y., Chow, S. T., Xie, W., Zhang, X., Zhou, J., and Chan, F. L. (2021). Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer. Mol Aspects Med 78, 100921.
3. Zhou, J., Wang, Y. *, Wu, D., Wang, S., Chen, Z., Xiang, S., and Chan, F. L. (2021). Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer. Oncogene 40, 2625-2634. (*Co-first author)
4. Xu, Z., Ma, T., Zhou, J., Gao, W., Li, Y., Yu, S., Wang, Y.#, and Chan, F. L. (2020). Nuclear receptor ERRalpha contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis. Theranostics 10, 4201-4216. (#Co-corresponding author)
5. Wang, Z., Li, Y., Wu, D., Yu, S., Wang, Y.# and Chan, F.L. (2019) Nuclear receptor HNF4 performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence. Oncogene 39, 1572-1589. (#Co-corresponding author)
6. Xiao, L., Wang, Y.*, Xu, K., Hu, H., Xu, Z., Wu, D., Wang, Z., You, W., Ng, C.F., Yu et al. (2018). Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis. Cancer Research 78, 2205-2218. (*Co-first author)
7. Xu, Z., Wang, Y.*, Xiao, Z.G., Zou, C., Zhang, X., Wang, Z., Wu, D., Yu, S., and Chan, F.L. (2018). Nuclear receptor ERRalpha and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer. Oncogene 37, 6259-6274. (*Co-first author)
8. Jia, L., Wu, D., Wang, Y.*, You, W., Wang, Z., Xiao, L., Cai, G., Xu, Z., Zou, C., Wang, F., et al. (2018). Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription. Oncogene 37, 3340-3355. (*Co-first author)
9. Wang, Z., Wu, D., Ng, C.F., Teoh, J.Y., Yu, S., Wang, Y.#, and Chan, F.L. (2018). Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer. Endocrine-Related Cancer 25, 35-50. (#Co-corresponding author)
10. Wang, Y., H. Hu, K. Xu, X. Wang, Y. Na and X. Kang (2015). Prevalence, risk factors and the bother of lower urinary tract symptoms in China: a population-based survey. International Urogynecology Journal 26, 911-919.
11. Wang, Y., H. Hu, K. Xu, X. Zhang, X. Wang, Y. Na and X. Kang (2015). Prevalence, risk factors, and symptom bother of nocturia: a population-based survey in China. World Journal of Urology 33, 677-683.
12. Hu, H., Y. L. Wang*, G. W. Wang, Y. C. Wong, X. F. Wang, Y. Wang and K. X. Xu (2013). A novel role of Id-1 in regulation of epithelial-to-mesenchymal transition in bladder cancer. Urologic Oncology: Seminars and Original Investigations 31, 1242-1253. (*Co-first author)
13. Wang, Y., K. Xu, H. Hu, X. Zhang, X. Wang, Y. Na and X. Kang (2011). Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China. Neurourology and Urodynamics 30, 1448-1455.